A Phase 1/2, Multi-Dose, Evaluator-Blinded, Randomized, Vehicle- and Standard of Care-Controlled Dose-Escalation Study to Assess Safety, Tolerability, and Pharmacokinetics of Topical Selinexor in Patients with Diabetic Foot Ulcers

Trial Profile

A Phase 1/2, Multi-Dose, Evaluator-Blinded, Randomized, Vehicle- and Standard of Care-Controlled Dose-Escalation Study to Assess Safety, Tolerability, and Pharmacokinetics of Topical Selinexor in Patients with Diabetic Foot Ulcers

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs Selinexor (Primary)
  • Indications Diabetic foot ulcer
  • Focus Adverse reactions
  • Sponsors Karyopharm Therapeutics
  • Most Recent Events

    • 23 Mar 2017 Planned End Date changed from 1 Jun 2016 to 1 Sep 2015.
    • 23 Mar 2017 Planned primary completion date changed from 1 Jun 2016 to 1 May 2015.
    • 23 Mar 2017 Planned initiation date changed from 15 Dec 2014 to 1 Jan 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top